MX2023014028A - Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos. - Google Patents
Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos.Info
- Publication number
- MX2023014028A MX2023014028A MX2023014028A MX2023014028A MX2023014028A MX 2023014028 A MX2023014028 A MX 2023014028A MX 2023014028 A MX2023014028 A MX 2023014028A MX 2023014028 A MX2023014028 A MX 2023014028A MX 2023014028 A MX2023014028 A MX 2023014028A
- Authority
- MX
- Mexico
- Prior art keywords
- chk1
- inhibitors
- checkpoint kinase
- methods
- checkpoint
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 title 2
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 101150113535 chek1 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193990P | 2021-05-27 | 2021-05-27 | |
| PCT/US2022/031141 WO2022251502A1 (en) | 2021-05-27 | 2022-05-26 | Checkpoint kinase 1 (chk1) inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014028A true MX2023014028A (es) | 2023-12-12 |
Family
ID=84229213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014028A MX2023014028A (es) | 2021-05-27 | 2022-05-26 | Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11707462B2 (enExample) |
| EP (1) | EP4347582A4 (enExample) |
| JP (1) | JP2024520481A (enExample) |
| KR (1) | KR20240021188A (enExample) |
| CN (1) | CN117715905A (enExample) |
| AU (1) | AU2022282384A1 (enExample) |
| BR (1) | BR112023024571A2 (enExample) |
| CA (1) | CA3219348A1 (enExample) |
| IL (1) | IL308759A (enExample) |
| MX (1) | MX2023014028A (enExample) |
| TW (1) | TW202313588A (enExample) |
| WO (1) | WO2022251502A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| CA3241992A1 (en) * | 2021-12-24 | 2023-06-29 | Seiji Kamioka | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) * | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1（chk1）抑制剂及其用途 |
| CN119255990A (zh) * | 2022-05-25 | 2025-01-03 | 曙方医药 | 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途 |
| EP4626433A1 (en) * | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| TW202440549A (zh) * | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4683635A1 (en) * | 2023-03-20 | 2026-01-28 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| JP2026513823A (ja) * | 2023-04-03 | 2026-05-01 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤の結晶形態およびその使用 |
| US20260232659A1 (en) * | 2023-04-03 | 2026-08-13 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| EP4753712A1 (en) * | 2023-08-02 | 2026-06-10 | Health Research, Inc. | Sequential treatment method for p53-deficient cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026108769A1 (en) | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof |
| WO2026108771A2 (en) | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted heteroaromatic compounds as inhibitors of checkpoint kinase 1 and notch signaling pathway and uses thereof |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN122031724A (zh) * | 2026-04-17 | 2026-05-15 | 中国科学院杭州医学研究所 | 编码p16蛋白的mRNA在制备用于治疗胰腺癌的药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| DZ3398A1 (fr) * | 2000-08-31 | 2002-03-07 | Pfizer Prod Inc | Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA3013514C (en) * | 2016-02-04 | 2021-11-23 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| KR20220042159A (ko) * | 2019-08-01 | 2022-04-04 | 인테그랄 바이오사이언스 피브이티. 엘티디. | 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도 |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| CN111253370B (zh) | 2020-03-24 | 2021-08-03 | 浙江大学 | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 |
| EP4741018A3 (en) * | 2020-06-19 | 2026-07-15 | Anaxis Pharma Pty Ltd | Sulphonamide compounds |
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| WO2022087326A1 (en) | 2020-10-23 | 2022-04-28 | Celgene Corporation | Heterocyclic compounds and their use for treatment of helminthic infections and diseases |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| CA3241992A1 (en) | 2021-12-24 | 2023-06-29 | Seiji Kamioka | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1（chk1）抑制剂及其用途 |
| CN119255990A (zh) | 2022-05-25 | 2025-01-03 | 曙方医药 | 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途 |
| JPWO2023229032A1 (enExample) | 2022-05-27 | 2023-11-30 | ||
| TW202440549A (zh) | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4626433A1 (en) | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| EP4683635A1 (en) | 2023-03-20 | 2026-01-28 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| JP2026513823A (ja) | 2023-04-03 | 2026-05-01 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤の結晶形態およびその使用 |
| US20260232659A1 (en) | 2023-04-03 | 2026-08-13 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
-
2022
- 2022-05-26 EP EP22812165.3A patent/EP4347582A4/en active Pending
- 2022-05-26 MX MX2023014028A patent/MX2023014028A/es unknown
- 2022-05-26 BR BR112023024571A patent/BR112023024571A2/pt unknown
- 2022-05-26 WO PCT/US2022/031141 patent/WO2022251502A1/en not_active Ceased
- 2022-05-26 TW TW111119737A patent/TW202313588A/zh unknown
- 2022-05-26 IL IL308759A patent/IL308759A/en unknown
- 2022-05-26 CA CA3219348A patent/CA3219348A1/en active Pending
- 2022-05-26 KR KR1020237044236A patent/KR20240021188A/ko active Pending
- 2022-05-26 CN CN202280052765.2A patent/CN117715905A/zh active Pending
- 2022-05-26 AU AU2022282384A patent/AU2022282384A1/en not_active Abandoned
- 2022-05-26 JP JP2023573047A patent/JP2024520481A/ja active Pending
- 2022-08-29 US US17/897,667 patent/US11707462B2/en active Active
-
2023
- 2023-06-01 US US18/327,775 patent/US12527790B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347582A1 (en) | 2024-04-10 |
| BR112023024571A2 (pt) | 2024-02-06 |
| AU2022282384A1 (en) | 2023-12-14 |
| KR20240021188A (ko) | 2024-02-16 |
| US12527790B2 (en) | 2026-01-20 |
| TW202313588A (zh) | 2023-04-01 |
| EP4347582A4 (en) | 2025-05-07 |
| IL308759A (en) | 2024-01-01 |
| CN117715905A (zh) | 2024-03-15 |
| JP2024520481A (ja) | 2024-05-24 |
| US20230026313A1 (en) | 2023-01-26 |
| CA3219348A1 (en) | 2022-12-01 |
| US11707462B2 (en) | 2023-07-25 |
| WO2022251502A1 (en) | 2022-12-01 |
| US20230310423A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024014500A (es) | Inhibidores piridinicos de la cinasa 1 de puntos de regulacion (chk1) y usos de estos | |
| BR112023024571A2 (pt) | Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos | |
| JOP20230190A1 (ar) | مركب كينازولين لتحفيز تحلل طافرة g12d لبروتين كيراس | |
| MX2023007193A (es) | Inhibidores de enpp1 y su uso para el tratamiento del cancer. | |
| MX2021009269A (es) | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| GEAP202516803A (en) | Bicyclic amines as cdk2 inhibitors | |
| CO2026004964A2 (es) | Moduladores de kras | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| EP4512480A3 (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| JOP20240237A1 (ar) | مركبات أريل غير متجانسة لمعالجة الألم | |
| CR7882A (es) | Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas | |
| CL2022000005A1 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112021019703A2 (pt) | Compostos heterocíclicos e usos dos mesmos | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| MX2019002121A (es) | Tratamiento conjunto para tratar el cancer de pancreas. | |
| MX2025001493A (es) | Inhibidores de cinasa dependiente de ciclina (cdk) 12 y/o cdk13 y usos de los mismos | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| CL2025001869A1 (es) | Uso de diferentes compuestos inhibidores de quinasas para tratar cáncer. | |
| MX2024003258A (es) | Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. |